Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-003565
Filing Date
2025-05-14
Accepted
2025-05-14 17:25:23
Documents
76
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR MARCH 2025 coeptis_i10q-033125.htm   iXBRL 10-Q 875940
2 CERTIFICATION coeptis_10q-ex3101.htm EX-31.1 7692
3 CERTIFICATION coeptis_10q-ex3102.htm EX-31.2 7830
4 CERTIFICATION coeptis_10q-ex3201.htm EX-32.2 2764
5 CERTIFICATION coeptis_10q-ex3202.htm EX-32.2 2359
  Complete submission text file 0001683168-25-003565.txt   5523190

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE coep-20250331.xsd EX-101.SCH 51178
7 XBRL CALCULATION FILE coep-20250331_cal.xml EX-101.CAL 59987
8 XBRL DEFINITION FILE coep-20250331_def.xml EX-101.DEF 245492
9 XBRL LABEL FILE coep-20250331_lab.xml EX-101.LAB 332174
10 XBRL PRESENTATION FILE coep-20250331_pre.xml EX-101.PRE 308275
78 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10q-033125_htm.xml XML 754173
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39669 | Film No.: 25947236
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)